Amarin Corp Plc (AMRN)

[sts66]

I'll be damned - TGs > 500 is part of the R-IT label - I did not know that - it also removes the actual indication AMRN filed for in the sNDA, which was reduce CVE risk for patients with TGs 150-499. It never occurred to me that a new indication label would include prior indications too - at first glance it would seem this means generics are infringing on R-IT, but FDA labels and patents are different animals.